Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.

PloS one - 1 Jan 2013

Saavedra Yascara Grisel Luna, Zhang Jianbing, Seidah Nabil G

Abstract excerpt

The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative regulator of the LDL receptor (LDLR) leading to its degradation in endosomes/lysosomes and up-regulation of plasma LDL-cholesterol levels. The proprotein convertases, a family of nine secretory serine proteases, are first synthesized as inactive zymogens. Except for PCSK9, all other convertases are activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Space
Share to Hep G2 Cells
Share to Immunoglobulin Fc Fragments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Proteolysis

Share to Receptors, LDL

Share to Serine Endopeptidases

Source

Open in PubMed Open full text

Identifiers

PMID: 23951290
DOI: 10.1371/journal.pone.0072113
PMCID: PMC3741231

Genes

PCSK9
LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.PMID 23951290Read ↗

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.Semantic proximity Read ↗

Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

A novel splicing variant of proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.Semantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

Unravelling the functional significance of PCSK9.Semantic proximity Read ↗

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.Semantic proximity Read ↗

Molecular basis of PCSK9 function.Semantic proximity Read ↗

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read ↗

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.